Repair effects of leramistat in participants with rheumatoid arthritis

A randomised, double-blind, placebo-controlled trial of the effects of leramistat (MBS2320) on muscle in participants with rheumatoid arthritis

Registry ID

ISRCTN16456769

Source registry

ISRCTN

Status

Recruiting

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

Istesso Therapeutics

Enrollment

18

Start date

2026-04-20

Completion date

2027-09-09

Last update

2026-08-17

Conditions

• Musculoskeletal Diseases

Summary

Rheumatoid arthritis

Detailed description

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Interventions

• DRUG: The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Inclusion criteria

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Exclusion criteria

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Locations

• , , United Kingdom
• , , England

Related clinical trials

• A feasibility study of an online support programme to help South Asian people newly diagnosed with rheumatoid arthritis manage their condition
• Intramedullary screws versus Kirschner wires (pins) for finger fractures
• The 3TR-PARTNER-RA study: Are RNA signatures (biomarkers) in the tissue which surrounds the joints (synovial tissue) from patients with early Rheumatoid Arthritis (symptoms <12 months) predictive of response to biologic drug treatments?
• Clinical study on 15 years follow up after neck surgery with Baguera®C device.
• Tailored physiotherapy rehabilitation after revision total hip replacement
• Imaging with a novel radioactive tracer called 99mTc-Maraciclatide to detect inflammation in the joint in individuals with arthritis

View on source registry